Change in Glycemic Control With Use of a Digital Therapeutic in Adults With Type 2 Diabetes: Cohort Study.
Mark A BermanNicole L GuthrieKatherine L EdwardsKevin J AppelbaumValentine Y NjikeDavid Miles EisenbergDavid L KatzPublished in: JMIR diabetes (2018)
Clinically meaningful reductions in HbA1c were observed with use of the FareWell digital therapeutic. Greater glycemic control was observed with increasing app engagement. Engagement and retention were both high in this widely distributed sample.